Half the Experts are Wrong (2.17.2023)
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
Simon Says “Don’t Do This” (1.27.2022)
Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.
Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
Worse Birth Outcomes in RA and SLE
A population-based retrospective cohort study patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE.
2022 Rheumatology Year in Review (1-6-2023)
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Best of 2022: Approach to ILD in Myositis Syndromes
Editor's note: this article originally appeared July 28, 2022, and is being shared again as a Best of 2022. Enjoy!
ACR22 Takeaways: Pre-RA, Lupus, PsA and AS
ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights.
ACR 2022 Appraisal, Praise & Critique (11.18.2022)
It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle.
I loved the city, but not the convention center (not easy to navigate).
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Don’t be ‘ticked’: TYK2 is not a JAK!
Recently the FDA approved deucravacitinib (DEUC), a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in systemic lupus erythematosus.
Social
FDA issued a drug safety warning linking thiopurine (AZA, 6MP) use in pregnancy & a rare risk of intrahepatic cholestasis of pregnancy (ICP). ICP has been reported in pts w/ CD, UC, or SLE; however thiopurines are not FDA approved for these Dx https://t.co/s37eRuAtQx
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Full-read Overview of Macrophage Activation Syndrome - a rare complication of autoimmune inflammatory rheumatic dz; assoc w/ Still’s disease SLE, Kawasaki, dermatomyositis, RA, Sjögren’s. Precipitating factors, including genetics & infections reviewed https://t.co/LmL3BPmo6c https://t.co/OkfwpzNLAL
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Our final TNR for the month of April will take place on 4/30 at 6:30pm ET.
Mastering SLE
Rethinking Pre-Clinical Disease in Lupus - David Karp, MD
Biology and Rx of Lupus Flares - Michelle Kahlenberg, MD
Current/Future Biomarkers in SLE - Andrea Fava, MD
https://t.co/IoRDAaAJbo https://t.co/C7HpKvehXX
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Single center retrospective 173 pts w/ CTD-ILD - 34% Sjogren’s, 30 RA, 25 systemic sclerosis, 6 UCTD, 3% idiopathic inflam myositis, 1,2% MCTD, 0.6% SLE. NSIP most common (60%) inSS & SSc; UIP more common in RA. 6 died, mostly infection https://t.co/IL2tnVDtoQ https://t.co/Ada49Qv5XL
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Full read overview of SJOGRENS SYNDROME, which can be Primary SS or Secondary (15% in SLE, 20% RA, & 30% systemic sclerosis). SS Organ involvement:
- CNS 2-17%
- Renal <=10%
- ILD 10-20%
-MSK 45-56%
https://t.co/RElOFfP2xr https://t.co/aJI041VCuE
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% CI 1.06, 1.47), acute lymphoblastic leukemia (OR =1.52), Burkitt lymphoma (OR=2.6) & CNS tumors (OR=1.45); same seen for RA mothers https://t.co/HQO972ch9R https://t.co/dDEJUo8unq
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually seen 2-10 wks post injx). Pts may or may not be symptomatic. CKD pts should have Ca and Creatinine monitored. https://t.co/UMYxjWz9n4 https://t.co/AG5wzBrY1Y
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Dr. Gabalawy: "How do you know what disease patients will develop in this preclinical autoimmunity state?"
@drdavidkarp "it's like when weeds pop up in a garden, it's random ...if ACPA Ab pops up, you might have RA, if it's dsDNA, maybe lupus." #RNL2024 @RheumNow https://t.co/JmDtaTt3sU
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 7 months ago
ICYMI @eular_org 2023 SLE Treatment guidelines https://t.co/BkGhwQtSor @rheumnow #RNL2024 https://t.co/troJ9D6AGm
Links:
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 7 months ago
Treatment of SLE. EULAR guidelines via @Kahlenberglab @RheumNow #RNL2024 https://t.co/a5lWfRLuh3
Richard Conway @RichardPAConway ( View Tweet )
1 year 7 months ago
